매출 흑자인데 영업CF 적자 (OCF/매출 -292%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
PeopleBio financial statements
KRX:304840 · KOSDAQ · Healthcare · sector #21PeopleBio's published financial data is dated 2026-11-15. 2024 revenue was KRW 3.73B. 2024 operating profit was −KRW 11.58B.
Reported results
Financial safety
Reference indicatorAs of 2024- Altman Z''
- -11.82
- Beneish M-Score
- -3.11
- Sloan accrual
- 0.01%
No statistical flag
These are factual indicators of distress and manipulation risk. They are not investment advice and are for reference only, as they have not yet been validated.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
Piotroski measures year-over-year financial improvement, not absolute quality.
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7 (new share issuance) is approximated by whether equity/assets was maintained (at least 95% of the prior year).
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
부채총계 급증 (+122%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -310.4%
- Interest coverage
- -10.8x
- Return on equity (ROE)
- -130%
Operating margin −5pp
Operating lossRevenue −15%
Interest coverage riskInterest rate +2pp
Interest coverage riskInterest coverage limit
Already below the limit by 339.1ppInterest coverage limit at an operating margin of 28.7%
Interest expense coverage threshold